뇌질환의 혁신, 뉴로벤티(NeuroVenti)

NEWS

Here's the news about NeuroVenti

Neuroventi, brain disease treatment platform 'Good-R&D Award'

페이지 정보

조회 464회 작성일 22-09-02

본문

Neuroventi, brain disease treatment platform 'Good-R&D Award'

22-09-02


Seo Dong-cheol, director of Neuroventi (right in the photo), won the 'Good-R&D Award' (Good-R&D Grand Prize) in the brain disease treatment platform category at the '2022 8th Korea Good Company Awards' hosted by Money Today held at the Korea Press Center on the 2nd. After winning the award, he is taking a commemorative photo with Jeong Hee-kyung, executive director of Money Today.


Neuroventi is a global bio venture company leading the development of an integrated treatment platform for brain development disorders and intractable brain diseases. We are developing the world's first autism spectrum disorder treatment through complex target precise control technology, and are preparing to apply for clinical trial 2nd phase IND (institutional trial plan). An official from the company said, "We are dreaming of becoming a company that gives hope to people suffering from incurable brain diseases such as autism by succeeding in developing first-in-disease drugs."